Loading, Please Wait...
MAYNARD, MA --(Marketwired - January 05, 2016) - Ischemix, Inc., a clinical-stage pharmaceutical company that has developed novel compounds for cytoprotection in the kidney, heart and other organ systems, announced today that David A. DeWahl, Jr., President and Chief Executive Officer, will present at the Biotech Showcase™ 2016 Conference to be held January 11 through January 13, 2016 in San Francisco, California.
Details of Ischemix' participation are as follows:
Event: Biotech Showcase™ 2016 Conference
Date: January 13, 2016
Time: 9:00 a.m. Pacific Time
Location: Parc 55 Wyndham Hotel San Francisco, Track E, Davidson Room
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential strategic partners.
About Ischemix, Inc.
Ischemix is a privately-held, clinical-stage pharmaceutical company that has developed novel compounds for cytoprotection in the kidney, heart and other organ systems. Ischemix' lead product candidate, CMX-2043, is in a Phase 2 trial for prevention of contrast-induced acute kidney injury and periprocedural cardiac injury. In a previous, successful Phase 2 trial, CMX-2043 demonstrated the ability to reduce cardiac injury in PCI patients. This breakthrough cytoprotective agent activates endogenous pathways of cell survival, enabling vital organs to survive acute challenges that can occur during medical treatment or hospitalization, including invasive cardiovascular procedures, serious infections and agents such as diagnostic contrast media. There are currently no drugs approved for these indications.
Hospital-acquired acute kidney injury (HA-AKI) is associated with increased morbidity, mortality and health care resource consumption. This injury is estimated to afflict approximately three million patients and cause 700,000 deaths worldwide every year. In the US, at least 1.8 million hospitalized patients are diagnosed annually with HA-AKI at a cost of at least $10 billion. The incidence of this injury progressing to renal failure and kidney dialysis has recently been increasing at 10% per year. Ischemix' first target within the overall HA-AKI population is patients at risk of contrast-induced acute kidney injury.
Injury to the heart arising during therapeutic cardiac catheterization (also called PCI or "stenting") and coronary artery bypass surgery (CABG) is a significant problem. There are approximately 600,000 PCIs and 400,000 CABG procedures in the US each year. Up to 16% of PCI patients, depending on the type of procedure being performed, are estimated to sustain a myocardial infarction (MI) during the procedure. As many as 20% of CABG patients suffer short- and long-term complications, including MIs.
David A. DeWahl, Jr.,
President and CEO